Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Dyslexia is the most common neurobehavioral disorder affecting children, with prevalence rates ranging from 17.5% to 21%. Studies have shown incomplete response to remediation and behavioural therapies in children with dyslexia. Evidence from neuroimaging studies as well as neuromodulation studies supporting a neurobiological basis of dyslexia is extensive according to which under-activation and poor connectivity in the underlying pathways for language and reading is the primary pathophysiology underlying reading difficulties. Evidence from studies on neuromodulation have shown that by combining remedial intervention with neuromodulation there is a synergistic effect through the mechanism of long term potentiation. In view of the above mentioned our study aims to investigate the role of Hf rTMS as an adjunct to AI enabled remedial intervention in children with dyslexia in improving their reading abilities.
AI enabled remedial intervention -
rTMS procedure
Follow up
Control - For controls investigators will be using the retrospective data of children with dyslexia who received AI enabled remedial intervention alone (for 6 weeks) as a part of a previous study by Dr Sayoni under the guidance of Prof Sheffali Gulati as Chief guide.
•Assessment Tools
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High frequency repetitive Transcranial Magnetic Stimulation | Experimental | Children who have given consent for the study and are fulfilling the inclusion and exclusion criteria will be enrolled and given Transcranial magnetic stimulation (TMS) as per protocol as described below over 12 week along with AI based remedial intervention. TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil 1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transcranial magnetic stimulation (Hf rTMS) | Device | TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil 1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in reading abilities of the participants as assessed by CTOPP-2 scores at 6 and 12 weeks from baseline. | Difference in mean of CTOPP-2 scores at 6 and 12 weeks from baseline. CTOPP-2 - Comprehensive Test Of Phonological Processing Tool, 2nd edition -tool has been explained in the study description section above. | From baseline to 6 and 12 weeks |
| Improvement in reading abilities of the participants as assessed by GLAD scores at 6 and 12 weeks from baseline. | Difference in mean of GLAD scores at 6 and 12 weeks from baseline. GLAD - Grade level Assessment Device Tool The tool has been explained in the study description section above. | From baseline to 6 and 12 weeks |
| Improvement in reading abilities of the participants as assessed by WRAT-5 scores at 6 and 12 weeks from baseline. | Difference in mean of WRAT5 scores at 6 and 12 weeks from baseline. WRAT-5 - Wide Range achievement test, 5th edition The tool has been explained in the study description section above. | From baseline to 6 and 12 weeks |
| Improvement in reading abilities of the intervention group (who received Hf-rTMS with AI based remedial intervention) as assessed by CTOPP-2 scores at 6 weeks as compared to controls (who received only AI based remedial intervention). | Difference in mean of change in CTOPP-2 scores at 6 weeks between the intervention group and the retrospective data of controls CTOPP-2 - Comprehensive Test Of Phonological Processing Tool, 2nd edition The tool has been explained in the study description section above. | From baseline to 6 weeks |
| Improvement in reading abilities of the intervention group (who received Hf-rTMS with AI based remedial intervention) as assessed by GLAD scores at 6 weeks as compared to controls (who received only AI based remedial intervention). |
| Measure | Description | Time Frame |
|---|---|---|
| To compare the domain wise change CTOPP-2 scores of participants pre and post intervention | Difference in mean of Domain wise CTOPP2 score at 6 and 12 weeks from baseline CTOPP-2 - Comprehensive Test Of Phonological Processing Tool, 2nd edition - details of the tools have been described in the study description section above. | From baseline to 6 and 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sheffali Gulati | Contact | 01126594679 | sheffaligulati@gmail.com | |
| Sheffali Gulati | Contact | 9810386847 | sheffaligulati1@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Sheffali Gulati | All India Institute of Medical Sciences, New Delh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| All India Institute of Medical Sciences | Recruiting | Delhi | 110029 | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004410 | Dyslexia |
| ID | Term |
|---|---|
| D007806 | Language Disorders |
| D003147 | Communication Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
| ID | Term |
|---|---|
| D050781 | Transcranial Magnetic Stimulation |
| ID | Term |
|---|---|
| D055909 | Magnetic Field Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Ambispective Quasi-experimental study design
Not provided
Not provided
Primary Outcome measures (GLAD, CTOPP2, WRAT-5) will be assessed by a clinical psychologist not involved in the study
Not provided
|
|
Difference in mean of change in GLAD scores at 6 weeks between the intervention group and the retrospective data of controls GLAD - Grade level Assessment Device Tool The tool has been explained in the study description section above.
| From baseline to 6 weeks |
| Improvement in reading abilities of the intervention group (who received Hf-rTMS with AI based remedial intervention) as assessed by WRAT5 scores at 6 weeks as compared to controls (who received only AI based remedial intervention). | Difference in mean of change in WRAT5 scores at 6 weeks between the intervention group and the retrospective data of controls WRAT-5 - Wide Range achievement test, 5th edition The tool has been explained in the study description section above. | From baseline to 6 weeks |
| To compare the domain wise change WRAT-5 scores of participants pre and post intervention | Difference in mean of Domain wise WRAT-5 score at 6 and 12 weeks from baseline WRAT-5 - Wide Range achievement test, 5th edition - details of the tools have been described in the study description section above | From baseline to 6 and 12 weeks |
| To evaluate the persistence of effect of Hf rTMS in children with dyslexia at 24 weeks as assessed by WRAT5 scores | Difference in mean of WRAT-5 scores at 24 weeks from 12 weeks and from baseline WRAT-5 - Wide Range achievement test, 5th edition The tool has been explained in the study description section above. | From baseline to 24 weeks from 12 weeks and |
| To evaluate the persistence of effect of Hf rTMS in children with dyslexia at 24 weeks as assessed by GLAD scores | Difference in mean of GLAD scores at 24 weeks from 12 weeks and from baseline GLAD - Grade level Assessment Device Tool The tool has been explained in the study description section above. | From baseline to 24 weeks from 12 weeks and |
| To evaluate the persistence of effect of Hf rTMS in children with dyslexia at 24 weeks as assessed by CTOPP-2 scores | Difference in mean of CTOPP-2 scores at 24 weeks from 12 weeks and from baseline CTOPP-2 - Comprehensive Test Of Phonological Processing Tool, 2nd edition The tool has been explained in the study description section above. | From baseline to 24 weeks from 12 weeks and |
| To evaluate the cortical excitability parameter - RMT pre and post intervention | Mean change in RMT from baseline at 6 weeks, 12 weeks and 24 weeks into the study RMT - Resting Motor Threshold | at 6 weeks, 12 weeks and 24 weeks into the study |
| To evaluate the resting state functional networks and brain activation profile during phonological tasks using functional MRI in dyslexic children pre and post intervention | Differences in functional connectivity and Difference in activation scores of ROI (region of Interest) during the phonological tasks on f MRI from baseline at 12 weeks (at end of intervention) | from baseline at 12 weeks (at end of intervention) |
| To describe adverse events noted during Hf rTMS | AE= Positive increase in any of the ROS (review of systems) criteria compared to pre therapy No of patients who have had atleast 1 AE AE rate: ratio of sessions with adverse events divided by total sessions | 12 weeks |
| To describe subjective improvement as assessed by parents and teachers of children with dyslexia | Subjective Improvement as assessed by the parent and teacher on a 7 point Likert scale | at 6 weeks, 12 weeks and 24 weeks from baseline |
| D009422 | Nervous System Diseases |
| D000067559 | Specific Learning Disorder |
| D007859 | Learning Disabilities |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |